Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott Kaletra

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Combination protease inhibitor lopinavir/ritonavir received accelerated approval from FDA Sept. 15, two and a half months after its NDA was submitted. Abbott expects to submit data for full approval within two years. The submission will contain final study reports on a head-to-head study with Pfizer/Agouron's Viracept (nelfinavir) and data from an open trial of Kaletra vs. investigator-selected PIs in combination with Roxane's Viramune (nevirapine) and two nucleoside reverse transcriptase inhibitors in previously treated patients. Kaletra is indicated for use "in combination with other antiretroviral agents for the treatment of HIV infection" in patients six months and older and is dosed twice daily. Abbott is conducting a 35-patient study of once-daily Kaletra administratio
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS001190

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel